SARS-CoV-2 ELISA
Krishgen has been at the forefront of the SARS-CoV-2 response, manufacturing various specific assays and tests from April 2020. These products have supported a variety of research, as well as vaccine and therapy development.
Krishgen offers 40+ specific assays for estimation of antigen and antibodies in human serum and plasma. This is the widest range of assays available in the world.
Primarily, Krishgen is working on accurate, specific ELISA for antigen, and antibody studies related to COVID-19. Whether you are working with Spike protein (RBD, S1 and S2) or N-protein, and with IgG or IgM, Krishgen has the right immunoassay for you. Our species-specific ELISA kits allow for antigen and antibody quantification in human as well as animal models.
Krishgen is currently the only company in the world commercially manufacturing several of these ELISA. If you require support in choosing the right product, get in touch with our technical support team today!
- validated as per EMA/FDA guidelines in line with ICH Code for Harmonization of Biological Assays.
- Produced in an ISO 13485 certified facility.
- Validated for human serum and plasma samples.
- Optimised to minimise lot-to-lot variation
- Developed using highly specific antibody pairs for detection and coating, with proprietary stabilizers and blockers for optimal noise:signal ratio.
- Recovery: 85 – 120%
- Lyophilized standards allow for stability.
- One of the only commercially available assays in the world for these peptide targets.
- Can be customised for animal serum or plasma to suit your sample type.
Kit Contents:
Kit contents may vary slightly. Please refer to product-specific inserts for a complete list of contents for each individual assay.
- Pre-coated 96-well Microplate
- Conjugated Detection Antibody
- Calibrated Immunoassay Standard
- Assay Diluent
- Calibrator Diluent(s)
- Wash Buffer
- Substrate
- Stop Solution
- Plate Sealers
Bridging Animal to Human Research
Krishgen’s range of 60+ ELISA for specific measurement of both antigen and antibodies to wild type and variants allow for a smooth bridging of research from animal models to human models. Our range of assays for Rat, Mouse, Hamsters and other animals are unique and highly specific.
Related Research Areas
Related Blogs
Featured Citations
| Wild Type | Alpha | Beta | Delta |
| Omicron |
SARS-CoV-2 ELISA
The outbreak in the city of Wuhan is caused by the highly infectious coronavirus 2019-nCoV, named by the World Health Organization on January 12nd, 2020. This new virus belongs to the Beta-coronavirus Genus, which also includes SARS CoV (2003) and MERS CoV (2012). The sequence similarity between 2019-nCoV and MERS-CoV is 40%, while that between 2019-nCoV and SARS-CoV is 70%.
Currently, scientists around the world are exploring all the potential strategies to develop an efficient vaccine against SARS-CoV-2. Most vaccine candidates for COVID-19 aim to induce neutralizing antibodies against the viral spike (S) protein, preventing uptake via the human ACE2 receptor and thereby blocking infection [3, 5, 6]. A striking feature of this COVID-19 vaccine development landscape is the diversity of technology platforms being evaluated, including:
Live attenuated vaccines: Use a modified live SARS-CoV-2 virus with reduced virulence (e.g. codon deoptimization or a mutated E protein [7]). This strategy can induce a quick and strong immune response but can be dangerous for immunosuppressed persons.
Viral-vector based vaccines: Use a viral backbone (e.g. adenovirus) to introduce a SARS-CoV-2 gene into the host. This strategy can enhance immunogenicity without an adjuvant and promotes a robust cytotoxic T cell response to eliminate virus-infected cells.
Recombinant protein-based vaccines: Use SARS-CoV-2 proteins (e.g. S protein) to elicit an immune response in the host. These vaccines are commonly developed in combination with an adjuvant for improved immunogenicity.
DNA vaccines: Use plasmid DNA to express antigens of SARS-CoV-2 for efficient delivery into the host cells. There are currently no approved DNA vaccines for humans.
mRNA vaccines: Encodes a SARS-CoV-2 antigen and uses a system such as a liposome for delivery into the host. There are currently no approved mRNA vaccines for humans.
If you are unable to locate your desired ELISA kit on our website, or have a technical query, please drop us a message and our team will come back to you with availability. If we do not have it available, we will suggest a feasible custom development option.
Require a Custom Assay?
Krishgen can develop and manufacture to your specific requirements.
Whether you require a change in the assay range or sensitivity, want an assay validated for a specific matrix or even want an novel immunoassay developed, the Krishgen team can support you. Get a free technical consultation to learn about the feasibility and timeline of your new assay.